Table 2.
Antiangiogenic agents targeting vascular endothelial growth factor signaling in clinical trials.
| Regimen | Phase | Sample | Cancer typle | Outcome |
|---|---|---|---|---|
| Bevacizumab, carboplatin and paclitaxel | IV | 398 | Ovarian cancer | Median PFS: 20.8 months median OS: 41.1 months |
| Apatinib vs. Placebo | III | 92 | Thyroid cancer | Median PFS: 22.2 months ORR: 54.3% DCR: 58.7% |
| Vandetanib and everolimus | I | 80 | Solid tumors | Median PFS: 4.1 months median OS: 10.5 months |
| Motesanib，paclitaxel, and carboplatin | III | 401 | Nonsquamous non-small-cell lung cancer | Median PFS: 5.6 months ORR: 60.1% |
| Pazopanib | II | 168 | Thyroid carcinoma | Best response rate: 35.6% DCR: 89.4% |
| Axitinib and pembrolizumab | Ib | 52 | Renal-cell carcinoma | Median PFS: 23.5 months ORR: 73.1% |
| Famitinib and camrelizumab | II | 33 | Cervical squamous cell carcinoma | Median PFS: 10.3 months 12-month duration of response rate: 74.1% |
| Lenvatinib | II | 52 | Thyroid cancer | 1 year overall survival rate: 11.9% ORR: 11.9% DCR: 73.8% |
| Cabozantinib | III | 258 | Thyroid cancer | Median PFS: 11.0 months |
| Regorafenib | II | 39 | Biliary tract cancer | ORR: 9.1% DCR: 63.6% |
PFS, progression-free survival; OS, overall survival; ORR, objective response rate; DCR, disease control rate.